Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 23

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 23
---
    233 |    -12 |   -12 |     9 |    -73 |              172 |     -4 |    -3 |     23 |      4 |     3 |              29 |      - |    -4 |
| Total Medicines    | 14,365 |     11 |     9 | 6,046 |      8 |            3,903 |     15 |    15 |  3,100 |     14 |     7 |           1,316 |      5 |     3 |

The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.

Table 28: Alliance Revenue: 9M 2025

| For thenine            
 monthsended 30         
 September              |  2025 
    $m |  2024 
    $m |
| Enhertu                | 1,291 | 1,045 |
| Tezspire               |   453 |   303 |
| Beyfortus              |   252 |    75 |
| Datroway               |    38 |     - |
| Other Alliance Revenue |    74 |    75 |
| Total                  | 2,108 | 1,498 |

Table 29: Collaboration Revenue: 9M 2025

| For thenine                 
 monthsended 30              
 September                   | 2025 
   $m | 2024 
   $m |
| Farxiga: sales              
 milestones                  |   81 |   52 |
| Beyfortus: sales            
 milestones                  |    - |   56 |
| Other Collaboration Revenue |   12 |    - |
| Total                       |   93 |  108 |

Table 30: Other operating income and expense: 9M 2025

| For thenine    
 monthsended 30 
 September      | 2025 
   $m | 2024 
   $m |
| Total          |  281 |  152 |

Other shareholder information

Financial calendar

Announcement of FY and Q4 2025 results: 10 February 2026

Dividend payment dates

Dividends are normally paid as follows:

First interim: Announced with the half year results and paid in September

Second interim: Announced with the full year results and paid in March

Contact details